Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Castle Biosciences, Inc. logo — Improving health through innovative tests that guide patient...

Castle Biosciences, Inc.

Improving health through innovative tests that guide patient care

Founded 2008 United States Friendswood, United States 744 employees Post Ipo Equity Total: $425.42M Biotechnology, Health Care

General Information

Company Name Castle Biosciences, Inc.
Founded Year 2008
Location United States Friendswood, United States +3
Employees 744
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Castle Biosciences, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Castle Biosciences, Inc.

Castle Biosciences, Inc. is a leading biotechnology company focused on innovative diagnostic tests that drive personalized patient care. Founded in 2008, the company operates from Friendswood, TX, with laboratory facilities in Phoenix, AZ, and Pittsburgh, PA. Castle Biosciences boasts a diverse portfolio of commercial and pipeline tests targeting unmet clinical needs across the patient care continuum. With a strong emphasis on patient benefits, the company's proprietary tests address critical clinical questions and treatment plan challenges in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. The company's flagship product, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that utilizes individual tumor biology to predict metastasis or recurrence risks and sentinel lymph node positivity for invasive cutaneous melanoma. In addition, DecisionDx®-SCC and DecisionDx®-UM offer valuable risk prediction for metastasis in patients with cutaneous squamous cell carcinoma and uveal melanoma, respectively. Furthermore, Castle Biosciences’ comprehensive diagnostic offerings, including myPath® Melanoma and DiffDx®-Melanoma, provide accurate results to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. Notably, TissueCypher® Barrett’s Esophagus represents the world’s first precision medicine test designed to predict the development of esophageal cancer in patients with Barrett’s esophagus. In December 2020, Castle Biosciences secured a substantial $266.80M Post-IPO Equity investment, reflecting investor confidence in the company's growth potential and the value it delivers to patients and healthcare providers through innovative diagnostic solutions. This investment signifies a pivotal moment for the company as it continues to expand its footprint in the healthcare and biotechnology industries. Castle Biosciences remains at the forefront of transforming disease management and improving patient outcomes through its pioneering diagnostic tests.

Taxonomy: Diagnostics, Precision medicine, Cancer testing, Gene expression profiling, Clinical decision support, Metastasis prediction, Cancer staging, Dermatology, Oncology, Esophageal cancer, Patient care, Medical technology, Investor relations

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 15 Dec 2020
Post-IPO Equity •••••• - 24 Jun 2020
Venture Round •••••• 1 •••• •••• 24 Jul 2019
Convertible Note •••••• 1 •••• •••• 18 Apr 2019
Venture Round •••••• 3
Investor Investor
•••• •••• 		11 Jun 2018

View All 15 Funding Rounds

FAQ About Castle Biosciences, Inc.

Improving health through innovative tests that guide patient care
Castle Biosciences, Inc. was founded in 2008.
Castle Biosciences, Inc. is headquartered in Friendswood, United States.
Castle Biosciences, Inc. operates in the following industries: Biotechnology, Health Care.
Castle Biosciences, Inc. has approximately 744 employees.
Castle Biosciences, Inc. has completed 15 funding rounds, raising a total of $425.42M. The latest funding stage is Post Ipo Equity.

We're actively collecting intelligence on Castle Biosciences, Inc..

Track Castle Biosciences, Inc. to get notified

Don't just browse. Track.

Signal Tracker monitors Castle Biosciences, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes